

# **Plasma Renin Activity**

A Non-Standard Approach for a Non-Standard Biomarker Assay

## **Fit-For-Purpose Validations**



### **EMA 2012**



EMEA/CHMP/EWP/192217/2009 Rev. 1 Corr. 2\*\*
Committee for Medicinal Products for Human Use (CHMP)

Guideline on bioanalytical method validation

"Methods used for determining quantitative concentrations of biomarkers used in assessing pharmacodynamic endpoints are **out of the scope** of this guideline"

### **FDA 2018**

Bioanalytical Method Validation Guidance for Industry "Biomarkers can be used for a wide variety of purposes during drug development; therefore, a fit-for-purpose (FFP) approach should be used when determining the appropriate extent of method validation"

### **Fit-For-Purpose Validations**





Points to Consider Document:
Scientific and Regulatory Considerations for the
Analytical Validation of Assays Used in the
Qualification of Biomarkers in Biological Matrices

June 11, 2019


Biomarker Assay Collaborative Evidentiary Considerations
Writing Group, Critical Path Institute (C-Path)

"...only the analytical elements directly relevant to the biomarker of interest and its Context of Use (COU) in drug development should be considered"

## The Renin-Angiotensin-Aldosterone System



The RAA system is the hormonal system which regulates blood volume, blood pressure and osmoregulation




Different enzymatic reactions in this system may be the target of drug mediated inhibition for the treatment of cardiovascular and kidney diseases

### How do you measure activity?

LGC

3.6e4



Activity Sample Incubated at +37°C

Baseline Sample Incubated at +4°C


0.0 1.2 3.0 Time, min

 $\frac{AngI\ conc\ in\ +37^{\circ}C\ sample\ -\ AngI\ conc\ in\ +4^{\circ}C\ sample}{3\ (Incubation\ period)}\ =\ PRA\ ng/mL/hour$ 

5

## Surrogate Analyte<sup>2</sup>: Angiotensin I





## Reference Range & Dilutions



Reference intervals vary between labs and with age, gender, race, diet, posture

-0.167 - 40.0 ng/mL/hr

Dilution of PRA samples should be avoided

| Undiluted Sample   | Baseline | Activity |
|--------------------|----------|----------|
| Ondiluted Sample   | Sample   | Sample   |
| Ang I conc (ng/mL) | 2.4      | 7.2      |
| PRA (ng/mL/hr)     | 1.60     |          |



### Activity is disrupted

This has an impact on activity QCs

## **Reference Range & Dilutions**



Reference intervals vary between labs and with age, gender, race, diet, posture

-0.167 - 40.0 ng/mL/hr

Dilution of PRA samples should be avoided

| Undiluted Sample   | Baseline | Activity |
|--------------------|----------|----------|
|                    | Sample   | Sample   |
| Ang I conc (ng/mL) | 2.4      | 7.2      |
| PRA (ng/mL/hr)     | 1.60     |          |



| Not Corrected for  | Baseline | Activity |
|--------------------|----------|----------|
| Dilution Factor    | Sample   | Sample   |
| Ang I conc (ng/mL) | 0.5      | 0.8      |
| PRA (ng/mL/hr)     | 0.10     |          |

### Activity is disrupted

This has an impact on activity QCs

## Reference Range & Dilutions



Reference intervals vary between labs and with age, gender, race, diet, posture

-0.167 - 40.0 ng/mL/hr

Dilution of PRA samples should be avoided

| Baseline | Activity      |
|----------|---------------|
| Sample   | Sample        |
| 2.4      | 7.2           |
| 1.60     |               |
|          | Sample<br>2.4 |



| Not Corrected for  | Baseline | Activity |
|--------------------|----------|----------|
| Dilution Factor    | Sample   | Sample   |
| Ang I conc (ng/mL) | 0.5      | 0.8      |
| PRA (ng/mL/hr)     | 0.10     |          |

| Corrected for      | Baseline | Activity |
|--------------------|----------|----------|
| Dilution Factor    | Sample   | Sample   |
| Ang I conc (ng/mL) | 2.6      | 4.1      |
| PRA (ng/mL/hr)     | 0.51     |          |

### Activity is disrupted

This has an impact on activity QCs

### **Matrix Effects**


#### Parallelism – Angiotensin I Only



#### Use of 20% Intralipid for hyperlipidaemic plasma

 Cannot distinguish between abnormal PRA in an individual vs the potential impact of hyperlipidaemic matrix

#### Matrix effect in 3% haemolysed samples




| Haemolysed Plasma    |      |
|----------------------|------|
| PRA (ng/mL/Hr)       | 1.86 |
| % Difference vs      | 20.6 |
| Un-haemolysed Sample | 39.6 |

## **Demonstrating Control: Angiotensin I**

LGC

Surrogate LLOQ, spiked plasma QC Med and QC High Incubated on ice for 3 hours



• Intra- and Inter-batch accuracy was ≤ 7.1%, precision ≤ 4.8%

## Is that a good control of renin activity?



#### The goal is reproducible PRA not Ang I...

| Analytical Run | PRA ng/mL/hr |
|----------------|--------------|
| Run 1          | 1.27         |
| Run 2          | 1.29         |
| Run 3          | 1.21         |
| Run 4          | 1.25         |
| Run 5          | 1.33         |
| Mean           | 1.27         |
| SD             | 0.04         |
| %CV            | 3.52         |

Assessed the precision of the incubation process in an endogenous pool across 5 analytical runs

- Intra-batch precision for Ang I in activity samples
   ≤6.5% CV
- Inter batch precision for PRA 3.5%


Accuracy?

## **Another Way to Demonstrate Control**



### Low, medium and high activity levels

| BioRad QC | PRA      |
|-----------|----------|
| Level 2   | ng/mL/hr |
| Run 1     | 2.87     |
| Run 2     | 2.55     |
| Run 3     | 2.59     |
| Run 4     | 2.49     |
| Run 5     | 2.80     |
| Mean      | 2.63     |
| SD        | 0.2      |
| %CV       | 6.5      |



#### Acceptance criteria

- · Clinical acceptance criteria?
- 4-6-X?

Context of Use!

# "Stability can only be attained by inactive matter"

LGC




"Currently, pre-analytical errors account for up to 70% of all mistakes made in laboratory diagnostics"

## **Stability and Pre-Analytical Factors**



Enzyme activity at ambient temperature




Substrate being used up before incubation


## **Stability and Pre-Analytical Factors**




### Cryo-activation of pro-renin



Pro-renin in frozen, ambient, and physiological temperatures



Pro-renin between -5°C and +4°C




Renin

May result in apparent PRA in sample which is higher than in vivo

## **Stability and Pre-Analytical Factors**

Did we see spontaneous generation of Ang I at RT?

- +67% Ang I in baseline sample after 24 hours
- -16% decrease in renin activity



Did we see cryo-activation of pro-renin?

- -0.8% change in renin activity after 24 hours at +4°C
- -3.4% change in renin activity after 4 freeze thaws







Pre-analytical factors addressed?




### You Need to Factor in the Individual!

Did we see spontaneous generation of Ang I at RT?

- +67% Ang I in +4°C sample after 24 hours
- -16% decrease in renin activity
- 0.7% change in PRA for Individual 1
- -29% change in PRA for Individual 2
- -14% change in PRA for Individual 3

Did we see cryo-activation of pro-renin?

- -0.8% change in renin activity after 24 hours at +4°C
- -3.4% change in renin activity after 4 freeze thaws
- No change in renin activity after 24 hours at +4°C
- 12% change in PRA for Individual 1 after 4 F/T
- 13% change in PRA for Individual 2 after 4 F/T
- 4.0% change in PRA for Individual 3 after 4 F/T









### ...Unwelcome Friends

LGC

Validated up to 1 month stability for Ang I in surrogate matrix however....

### Created a growth medium for something else

appeared at higher concentrations first!



## **Final Thoughts**



### Fit-for-purpose validation doesn't mean fewer assessments...

- 5x the stability work to ensure pre-analytical sample handling appropriate

#### Context of use

- What's the best way to demonstrate control?
- Is my acceptance criteria appropriate for the end use?

#### Do It Yourself

The literature is a guide not a gospel

# **Acknowledgements**



LGC, Fordham, UK

**Jodie Melling** 

Stephanie Keane

**Geoffrey Wallace** 

Michael Wright

Provincial Health Services Authority, Vancouver, British Colombia Dr. Grace van der Gugten